Page 4 - Daniel Mackey News Today : Breaking News, Live Updates & Top Stories | Vimarsana

CORBIN - The Corbin Tourism Commission approved increasing its Christmas decoration budget by $10,000 during a special-called meeting Wednesday.

A distant photo of the retirement party, published with permission from a local resident who drove past the event. At least six Southold Town Police Department employees are being questioned in an ongoing probe of the department’s response to community complaints about a sergeant’s retirement party last May, according to billing records filed with the town. As of Feb. 23, a police sergeant, one police officer and two dispatchers had been deposed by outside counsel hired by the Town Board to conduct the investigation. Two more officers were scheduled to be deposed, a...

Infant Bacterial Therapeutics AB: Infant Bacterial Therapeutics CFO leaves the company Infant Bacterial Therapeutics ABs CFO Daniel Mackey has decided to leave the company to pursue new challenges. He will remain in his current role during his notice period. Michael Owens will be acting CFO when Daniel leaves the company and until his replacement is in place. The recruitment process has already been initiated. "I would like to take this opportunity to thank Daniel and wish him every success in the future", says Staffan Strömberg, Chief Executive Officer of IBT. About Infant Bacterial Therape...

*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient: 1. Obtains access to the information in a personal capacity; 2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services; 3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional bod...

Infant Bacterial Therapeutics AB: Annual General Meeting of Infant Bacterial Therapeutics CEO speech About Infant Bacterial Therapeutics AB Infant Bacterial Therapeutics AB (publ) is a pharmaceutical company with a product in Phase III with a vision to develop drugs influencing the infant microbiome, and thereby prevent or treat rare diseases affecting infants. IBT is currently developing the drug candidate IBP-9414, for the prevention of necrotizing enterocolitis ("NEC") and improvement of feeding tolerance in premature infants. IBP-9414 contains the active substance Lactobacillus reuteri, ...